Tomoyuki Igawa, PhD

Head of Research at Chugai Pharmaceutical Co., Ltd.

Speaker

Tomoyuki Igawa, Ph.D., graduated and was awarded Ph.D. from the University of Tokyo for studies in Engineering, Chemistry, and Biotechnology. He started his career at Chugai Pharmaceutical, a member of the Roche group, and has led the effort to develop novel antibody engineering technologies and discover products, such as bispecific antibody for Hemlibra^® (emicizumab), recycling antibody for Enspryng^® (satralizumab) and PiaSky^® (crovalimab), half-life extension technology for Nemluvio^® (nemolizumab), and other various technologies applied to multiple Chugai/Roche pipeline products.

After serving as CEO/Research Head of Chugai Singapore and Associate Vice President, Head of Translational Research Division, he is currently the Vice President, Head of Research Division, responsible for planning, management, and execution of drug discovery research in Chugai. He has published > 40 peer reviewed papers and is an inventor of > 100 patents in antibody drug discovery.